ESBD_360338_1716477849236_Attachment P - 2024 Medical Renewal.pdf

Confidential Information of UnitedHealth Group

The Administrative Services Agreement is amended on January 1, 2024 as noted below.

This Amendment will not affect any of the terms, provisions or conditions of the Agreement except as stated herein.

The Prescription Drug List (PDL) subsection in Section A7 Pharmacy Benefit Services is hereby deleted and replaced in its entirety with the following:

Prescription Drug List (PDL). Customer will adopt one or more of United’s PDLs as the PDL. Upon termination of this Agreement, or if Customer terminates the pharmacy benefit services portion of this Agreement, Customer will stop all use of the PDL. United will make the PDL available to Customer or other appropriate parties. Except as provided in this Agreement, Customer will not copy, distribute, sell or otherwise provide United’s PDLs, to another party without United’s prior written approval. Provided that United agrees, Customer may post the PDL on Customer’s Participant health care website.

PDL Changes. United will include in the PDL new Prescription Drugs or other services or supplies as specified in the Plan. Following changes to the PDL, United, at Customer’s request, will provide or make available appropriate notifications of negative PDL changes to Customer, impacted Participants, and prescribers.

While Customer is the ultimate decision-maker on selecting the design of Customer’s PDL(s), Customer has requested that United supply and assist Customer with certain PDL development and management functions including but not limited to drug tiering decisions. United’s intent is to offer and provide Customer with the same PDL and management strategies that United develops and employs in the management of United’s fully insured business.

United makes the final classification of a Prescription Drug to a certain tier of the PDL by considering a number of factors including, but not limited to, clinical and economic factors. Clinical factors may include, but are not limited to, evaluations of the place in therapy, relative safety or relative efficacy of the Prescription Drug, as well as whether supply limits or notification requirements should apply. Economic factors may include, but are not limited to, the Prescription Drug's acquisition cost including, but not limited to, available Rebates, and assessments on the cost effectiveness of the Prescription Drug.

EXHIBIT B – FEES

These are the Fees Customer agrees to pay to United in exchange for the Services.

Medical Fees

The following financial terms are effective for the period January 1, 2024 through December 31, 2024, unless otherwise specified.

Average Contract Size: 1.99

Final Claims Fiduciary: United

Prescription Drug List: Flex Standard

The Fees include a Pharmacy Administrative Fee credit in the amount of $42.00 per Employee per month.

The Fees listed below are based upon an estimated minimum of 995 enrolled Employees.

$10.42 per Employee per month.

Customer acknowledges that UHC Hub products and services are offered and provided by third-party vendors that are not affiliated with United, and United disclaims any performance or financial return guarantees made by those third-party vendors. Customer agrees that United is not responsible or liable in any way for such performance or financial return guarantees. A third-party vendor’s participation in UHC Hub may terminate in the middle of the Initial Term or Renewal Term of this Agreement. In that instance, the product or service will no longer be provided from that vendor and no further Fees will be charged for that product or service. Fees for UHC Hub products and services will be paid through a withdrawal from the Bank Account. UHC Hub vendors are the following: Hinge Health, Kaia, LetsGetChecked, Livongo, Maven, Quest, 2nd MD, and Welldoc.

Credits

Wellness Allowance

United will provide a wellness allowance so Customer may enhance Customer medical benefits during the term of the Agreement. The wellness allowance may be used at Customer’s discretion as Customer utilizes wellness programming and services from United. If Customer terminates the Agreement prior to December 31, 2024, Customer will pay United a prorated portion of this credit.

$35,000 Wellness allowance

Payment Integrity Services

Service Description Fee

Advanced Analytics and Recovery

• United’s large-scale analytics to identify additional recovery opportunities.

• Claims re-examined every month for up to 12 months.

• Post-adjudicated claims.

24% of the gross recovery amount.

Coordination of Benefits (“COB”)

• Verify primary/secondary payer accuracy.

• Identify claims to be investigated using a layered approach to identify other primary payers:

1. Eligibility match to other commercial payers.

2. Eligibility match to Medicare.

• Correct pre-adjudicated claims prior to claim payment.

• Update claims systems with other primary/secondary payers’ information.

No additional Fee.

Service Description Fee

• COB indicators set to edit subsequent claims with primary/secondary payers’ information.

Credit Balance Recovery

• Review, validate, and recover credit balances (dollars) on existing patient accounts through a combination of analysis and technology.

• On-site at hospitals and facilities.

• Post-adjudicated claims.

10% of the gross recovery amount.

Focused Claim Review

• Review of claims for inappropriate billing of services not documented in clinical notes.

• Board certified, same-specialty medical directors.

Pre-adjudicated claims or post-adjudicated claims.

22% of the gross recovery or prevented amount.

Fraud, Waste, and Abuse Management

• Detection and recovery of wasteful, abusive, and/or fraudulent claims.

• Search claims for patterns which indicate possible waste or error by identifying specific claims for additional review.

• Evaluate claims to identify inappropriate levels of care, coding and/or resource utilization.

• Management can include pre-adjudicated claims or post-adjudicated claims.

22% of the gross recovery or prevented amount

Hospital Bill and Premium Audit Services

• In-depth review of hospital medical records or other related documentation compared to claimed amounts to ensure billing accuracy.

• Post-adjudicated claims.

22% of the gross recovery amount.

Litigation and Arbitration Fees for Recoveries

• Litigation, arbitration, or other judicial process to recover any Overpayments and other Plan recovery opportunities.

• Outside attorneys’ fees and costs or administrative process fees directly incurred with litigation, arbitration, or other judicial process.

• Pre-adjudicated claims or post-adjudication claims

Outside attorneys’ fees and costs will be deducted from the gross recovery prior to the assessment of any applicable United Fees (as indicated in this Exhibit).

Third Party Liability - Subrogation and Injury Coverage Coordination

• Services to prevent the payment of Plan benefits, or recover Plan benefits, which should be paid by a third party.

• Does not include benefits paid in connection with coordination of benefits, Medicare, or other Overpayments.

• Pre-adjudicated claims or post-adjudicated claims.

• Customer will not engage any entity except United to provide such services without prior United approval.

33.33% of the applicable savings amount.

Other Fees

Service Description Fee Naviguard Program

• Offers reimbursement methodologies for emergent and non-emergent out of network claims which calculates allowed amounts based on what a healthcare provider generally accepts for the same or similar service.

• Includes an advocacy component where Participants can access resources, and on-line tools and materials

$2.50 per Employee per month

Service Description Fee to help Participants stay in network and where assistance is provided in explaining reimbursement methodologies.

• For claims above a threshold established by United, the advocacy component includes United negotiating with a provider on behalf of a Participant with respect to Participant’s balance billed amount (e.g., non-emergent, choice claim).

• If the provider objects to what it was paid from the application of the allowed amount, or member contacts United for support with resolving a balance bill, United will increase compensation for a particular claim if: (a) United reasonably concludes that the particular facts and circumstances related to a claim provide justification for reimbursement greater than that which would result from the application of the allowed amount, and (b) United believes that it would serve the best interests of the Plan and its Participants (including interests in avoiding costs and expenses of disputes over payment of claims).

External Reviews If and when applicable, for each subsequent external review beyond the limited number of free reviews based upon Customer’s total enrollment, a Fee of $500 will apply per review.

Interest Rate on Unpaid Fees and Underfunding Bank Account

Prime rate plus 4%

Run-out Claims Administration

6 months of runout No charge after the Initial Term.

Livongo Chronic Condition Management $69.00 per Participant per month Pharmacy Benefit Rebates - Termination Pursuant to the termination section of this Agreement, if Customer terminates the Pharmacy Benefit Services portion of this Agreement only during the Term of the Agreement and termination is for any reason other than for cause, United may retain all Rebates that have not been remitted to Customer as of the effective date of such termination.

Medical Benefit Drug Rebate Compensation 80% to Customer, the balance is retained by United as compensation for the services.

Allocation and Payment of Gene Therapy Medical Benefit Drug Rebates

If Customer purchases gene therapy stop loss through United or an affiliate, United will retain rebates for gene therapy drugs when Customer is reimbursed by stop loss for any gene therapy claim.

Consolidated Appropriations Act, 2021 (“CAA”) Support Services. United will support Customer’s compliance with the requirements of the CAA, including the No Surprises Act (“NSA”), by the respective enforcement date as follows:

• NSA medical billing and the independent dispute resolution (“IDR”):

o United will determine if a claim is subject to the

NSA billing protections.

o If United and a provider are unable to come to an agreement within the prescribed negotiation period for a claim subject to the NSA billing protections, United will manage, direct, and make decisions and submissions to support the IDR for Customer.

o All qualifying payment amounts under the NSA will be calculated based on an insurance market

For the 2024 plan year, United will not charge separate services Fees outside of base rates for the CAA Support Services. United shall notify Customer of United’s intent to apply a charge for any support services or information provided if additional regulatory guidance changes the final compliance requirements.

Customer remains responsible for the government agency administration assessment and fees charged by the IDR arbitrator.

Service Description Fee across all self-insured group health plans administered by United.

o United will not be using third party provider networks for services covered by the NSA.

o The Fees for programs in which the parties share in the savings achieved off a provider’s billed charge will continue to apply to all services covered under the NSA.

o Customer shall fund all settlement amounts and payments required as a result of any IDR process decision through the Bank Account.

o Customer shall fund the IDR administration fee and all IDR arbitrator fees through the Bank Account.

• Revised medical Plan ID cards (if United provides Plan Participants with ID cards currently).

• Provider directory enhancements.

• Continuity of care and external appeals support for surprise medical bills.

• Support related to Mental Health Parity Non-

Quantitative Treatment Limitations audits initiated by the U.S. Department of Labor, U.S. Department of Health and Human Services or the U.S.

Department of Treasury.

• Provide language to support Customer’s anti-gag clause attestation requirement.

• Prepare and file pharmacy benefits and drug cost reports.

• Prepare and file air ambulance claims reports.

• Provide and maintain price comparison information to Participants by telephone and online.

Health Plan Transparency in Coverage Rule (“TiC”) Support Services. United will support Customer’s compliance with the requirements of the TiC by the respective enforcement date as follows:

• Machine-readable files accessible via a publicly available website, which Customer will be able to access and link to Customer’s own website.

• A cost estimator tool available online for Plan Participants for the items and services as required each year.

For the 2024 plan year, United will not charge separate services Fees outside of base rates for the TiC Support Services.

Disclosure: A United affiliate provides payment services to the healthcare industry and offers medical providers with various payment methods and options, including electronic payments, virtual cards and checks. Some options are available to medical providers for a fee and may result in the receipt of transaction fees or other compensation (e.g., 1% to 3% of the total transaction amount, or at the election of the provider a per transaction fee of up to $10) by a United affiliate. This has no impact on the Fees paid by Customer under this Agreement.

Dental Fees

The following financial terms are effective for the period January 1, 2024 through December 31, 2024, unless otherwise specified.

The Fees listed below are based upon an estimated minimum 1,032 enrolled Employees.

$3.36 per Employee per month.

Average Contract Size: 2.02

Run-out Claims Administration: 12 months of runout; no charge after Initial Term.

COBRA Fees

The following financial terms are effective for the period January 1, 2024 through December 31, 2024, unless otherwise specified.

NOTE: UnitedHealthcare will retain the 2% COBRA administration fee that is routinely charged to enrolled COBRA participants

COBRA Billing Set Up and Maintenance Year One

Group Setup Fee (one time fee at implementation) Included

COBRA Continuant Takeover Charge (one-time charge per current continuant from previous COBRA administrator) Included

On-going Maintenance Fee (annual fee in subsequent years after implementation) n/a

COBRA Services

Ongoing COBRA Continuant Per Month Charge $4.50

Qualifying Event Notification (QEN) includes distribution of QENs and election forms via proof of mail with instructions, and processing of enrollment forms returned (per notice) $14.50

COBRA / HIPAA Initial Rights Notifications (per notice) AKA New Hire Notification $3.00

Women's Health Cancer Rights Act (WHCRA) Notices (per notice) Included

State Continuation Notification (per notice) Included

Past Due Notices to Continuants (per notice, upon request) Included

Direct (Retiree) Billing Services

Direct (Retiree) Billing (per continuant per month) $4.50

Past Due Notices to Continuants (per notice, upon request) Included

The following are Optional Employee Notification Services Available to customers purchasing COBRA/Direct Bill Services

Retro COBRA / HIPAA Initial Rights Notices (per notice) $3.00

Post-COBRA HIPAA Certificates of Coverage on outside COBRA members (per certificate)* $3.00

HIPAA Privacy Notices (per notice) $3.00

Medicare-D Notifications $0.95

Open Enrollment Services

Open Enrollment Service (per person):

Includes packaging and distribution of all related benefit materials and/or informational documents as designated by and provided by the client

*There is a $100 minimum for Open Enrollment Services

$8.00 Plus Postage

*We provide these certificates through our internal processes as part of standard services for UnitedHealthcare members.

EXHIBIT C – GUARANTEES

The Fees at risk do not include Customer-elected optional and non-standard programs Fees, all credits, Payment Integrity Programs Fees, Out-of-Network Programs Fees, Commission Funds, Consultant Funds, and ancillary product Fees.

The Fees payable by Customer under this Agreement will be adjusted through a credit to Customer’s Fees in accordance with the guarantees set forth below unless otherwise defined in the guarantee. Unless otherwise specified, these guarantees are effective for the period beginning January 1, 2024 through December 31, 2024 (“Guarantee Period”). With respect to the aspects of United’s performance addressed in this exhibit, these Fee adjustments are Customer’s exclusive financial remedies.

United shall not be required to meet any of the guarantees provided for in this Agreement or amendments thereto to the extent United’s failure is due to Customer’s actions or inactions or if United fails to meet these standards due to fire, embargo, strike, war, accident, act of God, acts of terrorism or United’s required compliance with any law, regulation, or governmental agency mandate or anything beyond United’s reasonable control.

Prior to the end of the Guarantee Period, and on the condition that this Agreement remains in force, United may specify to Customer in writing new guarantees for the subsequent Guarantee Period. If United specifies new guarantees, United will also provide Customer with a new Exhibit that will replace this Exhibit for that subsequent Guarantee Period.

Claim is defined as an initial and complete written request for payment of a Plan benefit made by an enrollee, physician, or other healthcare provider on an accepted format. Unless stated otherwise, the claims are limited to medical claims processed through the claims systems. Claims processed and products administered through any other system, including claims for other products such as vision, dental, flexible spending accounts, health reimbursement accounts, health savings accounts, or pharmacy coverage, are not included in the calculation of the measurements.

Also, services provided under capitated arrangements are not processed as a typical claim, therefore capitated payments are not included in the measurements.

In the event any of the terms herein are inconsistent with the requirements of any federal, state or other applicable law or regulation, then the inconsistent terms will be null and void and United will have the right to revise, reprice or revoke this arrangement.

Claim Operations Time to Process in 10 Days

Definition The percentage of all claims United receives will be processed within the designated number of business days of receipt.

Measurement Percentage of claims processed 94% Time to process, in business days or less after receipt of claim business days 10

Criteria Standard claim operations reports Level Site Level Period Annually Payment Period Annually Fees at Risk Total Dollars at Risk for this metric $857 Payment Amount Of the Fees at Risk for this metric, percentage at risk for each gradient 20% Gradients 11 business days 12 business days 13 business days 14 business days 15 business days or more

Procedural Accuracy Definition Procedural accuracy rate of not less than the designated percent.

Measurement Percentage of claims processed without procedural (i.e. non-financial) errors 97% Criteria Statistically significant random sample of claims processed is reviewed to determine the percentage of claim dollars processed without procedural (i.e. non-financial) errors.

Level Office Level

Period Annually Payment Period Annually Fees at Risk Total Dollars at Risk for this metric $857 Payment Amount Of the Fees at Risk for this metric, percentage at risk for each gradient 20% Gradients 96.99% - 96.50% 96.49% - 96.00% 95.99% - 95.50% 95.49% - 95.00% Below 95.00%

Dollar Accuracy (DAR) Definition Dollar accuracy rate of not less than the designated percent in any quarter.

Measurement Percentage of claims dollars processed accurately 99% Criteria Statistically significant random sample of claims processed is reviewed to determine the percentage of claim dollars processed correctly out of the total claim dollars paid.

Level Office Level Period Annually Payment Period Annually Fees at Risk Total Dollars at Risk for this metric $857 Payment Amount Of the Fees at Risk for this metric, percentage at risk for each gradient 20% Gradients 98.99% - 98.50% 98.49% - 98.00% 97.99% - 97.50% 97.49% - 97.00 Below 97.00%

Member Phone Service Phone service guarantees and standards apply to Participant calls made to the customer care center that primarily services Customer’s Participants. If Customer elects a specialized phone service model the results may be blended with more than one call center and/or level. They do not include calls made to care management personnel and/or calls to the senior center for Medicare Participants, nor do they include calls for services/products other than medical, such as mental health/substance abuse, pharmacy (except when United is Customer’s pharmacy benefit services administrator), dental, vision, Health Savings Account, etc.

Average Speed of Answer Definition Calls will sequence through United’s phone system and be answered by customer service within the parameters set forth.

Measurement Percentage of calls answered 100%

Time answered in seconds, on average seconds 30 Criteria Standard tracking reports produced by the phone system for all calls Level Team that services Customer’s account Period Annually Payment Period Annually Fees at Risk Total Dollars at Risk for this metric $857 Payment Amount Of the Fees at Risk for this metric, percentage at risk for each gradient 20% Gradients 32 seconds or less 34 seconds or less 36 seconds or less 38 seconds or less Greater than 38 seconds

Abandonment Rate Definition The average call abandonment rate will be no greater than the percentage set forth Measurement Percentage of total incoming calls to customer service abandoned, on average 1.80% Criteria Standard tracking reports produced by the phone system for all calls Level Team that services Customer’s account Period Annually Payment Period Annually Fees at Risk Total Dollars at Risk for this metric $857 Payment Amount Of the Fees at Risk for this metric, percentage at risk for each gradient 20% Gradients 1.81% - 2.30% 2.31% - 2.80% 2.81% - 3.30% 3.31% - 3.80%

Greater than 3.80% Call Quality Score

Definition Maintain a call quality score of not less than the percent set forth Measurement Call quality score to meet or exceed 93% Criteria Random sampling of calls is each assigned a customer service quality score, using United’s standard internal call quality assurance program.

Level Office that services Customer’s account Period Annually Payment Period Annually Fees at Risk Total Dollars at Risk for this metric $857 Payment Amount Of the Fees at Risk for this metric, percentage at risk for each gradient 20% Gradients 92.99% - 91.00% 90.99% - 89.00% 88.99% - 87.00% 86.99% - 85.00% Below 85.00%

Satisfaction

Employee (Member) Satisfaction Definition The overall satisfaction will be determined by the question that reads “Overall, how satisfied are you with the way we administer your medical health insurance plan?”

Measurement Percentage of respondents, on average, indicating a grade of satisfied or higher 80% Criteria Operations standard survey, conducted over the course of the year; may be customer specific for an additional charge.

Level Office that services Customer’s account Period Annually Payment Period Annually Fees at Risk Total Dollars at Risk for this metric $429 Payment Amount Of the Fees at Risk for this metric, percentage at risk for each gradient N/A Gradients Not applicable

Customer Satisfaction Definition The overall satisfaction will be determined by the question that reads “How satisfied are you overall with

UnitedHealthcare?”

Measurement Minimum score on a 10-point scale score 5 Criteria Standard Customer Scorecard Survey Level Customer specific Period Annually Payment Period Annually Fees at Risk Total Dollars at Risk for this metric $429 Payment Amount Of the Fees at Risk for this metric, percentage at risk for each gradient N/A Gradients Not applicable

Pharmacy Financials

Definition Pharmacy rate guarantees.

Measurement 01/01/2024 and Criteria Combined Discount Guarantee - Broad Network Retail Brand, Average Wholesale Price (AWP) less 19.50% Retail Brand -- 90 Day Supply, AWP less

23.00%

Retail Generic - 30 and 90 Day Supply, AWP less

84.00% Mail Order Brand, AWP less

25.50%

Mail Order Generic, AWP less 87.00% The Guaranteed Discount amount will be determined by multiplying the AWP by the guaranteed discount off AWP by each component and adding the amounts together.

Dispensing Fees - Broad Network Retail Brand - 30 Day $0.49

Retail Brand -- 90 Day Supply

$0.06 Retail Generic - 30 Day

$0.49

Retail Generic -- 90 Day Supply $0.06 Dispensing fee totals are calculated by multiplying the actual scripts for each type by the contracted rate for that script type.

Fixed Rebate Guarantee Basis, per script

Brand

Retail - 30 and 90 Day

$456.87 Mail Order $464.04

Specialty Included In Retail

Included In Retail

Included In Retail

Credits and Allowances

Administrative Fee Credit (PEPM) $42.00

Level Customer Specific Period Annually Payment Period Annually Payment Amount -- Discounts

The amount the actual discounts are less than the combined guaranteed Retail, Mail, and Specialty discount amount.

Payment Amount -- Dispensing Fees

The amount the combined actual dispensing fee exceeds the combined contracted dispensing fee.

Payment Amount -- Rebates

The amount the combined actual Rebate amount is less than the combined guaranteed Rebate amount.

Conditions Discount & Dispense Fee Specific Conditions

• Discounts are based on actual Network Pharmacy brand and generic usage of retail and mail order drugs.

The guaranteed discount amount will be determined by multiplying the AWP by the contracted discount rate off AWP by component.

• Does not apply to items covered under the Plan for which no AWP measure exists.

• Discounts calculated based on AWP less the ingredient cost; discount percentages are the discounts divided by the AWP. Discounts for retail and mail order generic prescriptions represent the average AWP based on savings off Maximum Allowable Cost (MAC) pricing for MAC generics and percentage discount savings off AWP for non-MAC generics. All other discounts represent the percentage discount savings off of AWP.

• The arrangement excludes generic medications launched as an 'at-risk' product, generic medication with pending litigation, compound drugs, retail out of network claims, mail order drugs (for dispensing fee arrangement) and Indian Health Service Claims.

• The Arrangement excludes usual & customary claims, vaccines, long term care facility claims.

• The Arrangement includes veterans’ affairs facility claims, over-the-counter claims.

• The 90 day supply Retail guarantee includes drugs dispensed for 84 days or greater.

• The Mail Order guarantee includes drugs dispensed for 46 days or greater.

• When a drug is identified as a brand name drug, it will be considered a brand name drug for the calculation of discount guarantees. When a drug is identified as a generic drug, it will be considered a generic drug for the calculation of discount guarantees.

• Specialty drugs dispensed outside United's specialty Pharmacy Network are included in the retail guarantees. Specialty drugs dispensed through United's specialty Pharmacy Network are excluded from the Retail and Mail guarantees.

• Drugs in the following Specialty therapeutic categories are included in the retail guarantees: None.

Rebate Specific Conditions

• Client directed deviations from the PDL and PDL exclusions or uptiers, or clinical programs may result in changes to pricing and guarantees, which will be factored in at the time of rebate payment and/or reconciliation.

• Calculation of the guaranteed rebate amount will exclude ineligible claims including:

- claims where the plan is not the primary payer (e.g., coordination of benefits and subrogation claims)

- claims approved by formulary exception

- claims not covered by Customer's benefit design or PDL

- claims receiving 340B pricing

- long term care pharmacy claims

- federal government pharmacy claims

- claims for non-FDA approved products

- compound drug claims

- direct member reimbursement claims

• Devices are excluded from the claim counts; Insulins and Test Strips are not excluded.

• Vaccines are excluded from the claim counts.

• Rebate guarantee payments or reconciliations may be adjusted in the event of a change impacting the level of Rebates due to the introduction of therapeutically equivalent, lower Rebate drugs (e.g. biosimilar, authorized brand alternative, lower cost non-Generic Drug alternative) or the reduction of Wholesale Acquisition Cost on a Brand Drug subject to Rebates. In the event a payment or reconciliation adjustment is required, such adjustment will be based on the difference between a) pharmaceutical manufacturer revenue prior to the introduction of the lower Rebate drugs and b) the actual pharmaceutical manufacturer revenue received after the introduction of the lower Rebate drugs. Such adjustment does not apply to Generic Drugs that launch after the Brand Drug no longer has patent protection.

• The Rebate guarantees and any Administrative Fee Credits funded by retained Rebates set forth herein do not incorporate the impact of the elimination of the Average Manufacturer’s Price (AMP) Cap pursuant to the American Rescue Plan Act of 2021. United reserves the right to modify or eliminate any Rebate guarantees and Administrative Fee Credits once it has been able to determine that impact and the resulting changes to Rebates received from pharmaceutical manufacturers.

United reserves the right to modify or eliminate this arrangement as follows based upon changes in Rebates:

• if changes made to United's PDL, for the purpose of achieving a lower net drug cost for Customer and United's other ASO customers, result in significant reductions to the Rebate level

• in the event that there are material deviations to the anticipated timing of drugs that will come off patent and no longer generate Rebates

• if there is a change impacting the availability or amount of Rebates offered by drug manufacturer(s), including changes related to the elimination or material modification of a drug manufacturer(s) historic models or practices related to the provision of Rebates

• United will pay Fixed Rebates consistent with the Agreement. To the extent Rebates paid to United exceed the Fixed Rebate amount, We will retain the excess, including any Rebates United may earn on prescription drug products in any tiers not included in this arrangement and any related interest.

• Specialty rebates are included in the guaranteed retail per-script rebates above.

• Rebate Administrative Fee: United maintains systems and processes necessary for managing and administering Rebate programs. As consideration for these efforts, pharmaceutical manufacturers pay United administrative fees in addition to Rebates. Rebate Administration fees are included in the guaranteed rebate arrangement.

• If Customer terminates pharmacy benefit services with United prior to the end of the Pharmacy Pricing Term, United will retain any and all pending or future Rebates payable under the Agreement as of the effective date of the termination of pharmacy benefit services.

• Drugs in the following Specialty therapeutic categories are included in the retail per-Brand guarantees:

None.

Credits and Allowances

• Administrative Fee Credit: In addition to the guaranteed Rebates, Customer will receive an administrative fee credit. Under this arrangement, Rebates retained by United are used to lower the medical administration fee.

General Conditions

• All pricing guarantees shall remain in effect for the entire contract period of 01/01/2024 through 12/31/2024 ("Pharmacy Pricing Term"). Each twelve month period is a Guarantee Period.

• Specialty drugs typically covered under the medical benefit (administered / handled by a provider, administered in a physician's office, ambulatory or home infusion), and/or transitioned to the pharmacy benefit, are excluded from all guarantees.

• Drugs, products, supplies approved, covered and/or prescribed for the diagnosis, treatment or prevention of COVID-19 are excluded from all guarantees.

• On mail order drugs, specialty drugs, and retail pharmacy drugs and services including dispensing fees, United will retain the difference between what United reimburses the Network Pharmacy and Customer's payment for a prescription drug product or service.

• Pricing and guarantees assume enrollment of 995 Employees and 1,981 Participants; pricing and guarantees may be revised or withdrawn if actual enrollment varies by 10% or more from assumptions.

• The lesser of three logic (non-ZBL) will apply to Participant payments. Participants pay the lesser of the discounted price, the usual and customary charge or the cost share amount.

• All pricing guarantees require the selection of United as the exclusive mail provider.

United will have no financial guarantee obligation under the Agreement for any partial Guarantee Period if Customer terminates with an effective date prior to the end of the Pharmacy Pricing Term.

• United reserves the right to revise or revoke this arrangement if: a) changes in federal, state or other applicable law or regulation require modifications; b) there are material changes to the AWP as published by the pricing agency that establishes the AWP as used in these arrangements; c) Customer makes benefit changes that impact the arrangements; d) there is a material industry change in pricing methodologies resulting in a new source or benchmark; e) it is not accepted within ninety (90) days of the issuance of our quote; f) if Customer changes their mail service benefit; g) Customer utilizes a vendor, that facilitates steering members to different drugs or pharmacies to the extent these services impact the financial guarantees under this Agreement.

Brand / Generic Reconciliation Definition

• Brand Drug: An FDA approved drug, or a drug that is designated by FDA a DESI (Drug Efficacy Study Implementation) drug, or product, which is manufactured and distributed by an innovator drug company, or its licensee , set forth in Medi-Span’s National Drug Data File as a brand drug identified by all of the products meeting at least one of the following criteria:

- Medi-Span Multi-Source Code ("MSC") is equal to M, O, or N.

• Generic Drug: An FDA approved drug, or a drug that is designated by FDA a DESI (Drug Efficacy Study Implementation) drug, or product, that is therapeutically equivalent to other pharmaceutically equivalent products, as set forth in Medi-Span’s National Drug Data File as a generic drug identified by all products meeting at least one of the following criteria:

- Medi-Span Multi-Source Code ("MSC") is equal to Y.

TRRX

(05/2023)

Specialty Pharmacy

Specialty Pharmacy Discount Guarantee

Definition Specialty drug discount level based on actual specialty drug utilization for the specialty drugs dispensed through United's specialty Pharmacy Network. United reserves the right to change the designation of a drug from specialty to non-specialty based on market conditions.

Measurement Discount targets for individual drugs dispensed through United's specialty Pharmacy Network.

See chart below.

Specialty drugs not included on the list below and dispensed through United's specialty Pharmacy Network will be guaranteed at a discount of 14.0%.

Criteria Actual utilization, using Average Wholesale Price (AWP) in dollars, using our data, of specialty drugs through our specialty Pharmacy Network will be multiplied against the discount targets for the individual drugs to determine the overall discount target dollars. This total will be compared to actual discounts achieved for these drugs during the Guarantee Period.

The overall discount target dollars may be adjusted based on utilization of unlisted drugs to which the separate 14.0% discount applies. This total will be compared to actual discounts achieved for these drugs during the Guarantee Period.

Level Customer Specific Period Annual Payment Period Annual Payment Amount The amount the actual discounts are less than the combined guaranteed Retail, Mail, and

Specialty discount amount.

Conditions • Discounts calculated based on the AWP less the ingredient cost; discount percentages are the discounts divided by the AWP. Discounts for retail generic prescriptions represent the average savings off AWP based on Maximum Allowable Cost (MAC) pricing for MAC generics and percentage discount savings off AWP for non-MAC generics. All other discounts represent the percentage discount savings off of AWP.

• Specialty drugs dispensed outside United's specialty Pharmacy Network and drugs for which no AWP measure exists are excluded.

• Listed drugs which cease to be defined as specialty drugs during the Guarantee Period will be reconciled outside of the Specialty Pharmacy guarantee in the channel in which they are dispensed (retail or mail order).

• Limited Distribution (LDD) status is subject to change based on manufacturer decision.

• Specialty drugs typically covered under the medical benefit (administered / handled by a provider, administered in a physician's office, ambulatory or home infusion), and/or transitioned to the pharmacy benefit, are excluded from all guarantees.

• United reserves the right to revise or revoke this guarantee if: a) material changes in federal, state or other applicable law or regulation require modifications; b) there are material changes to the AWP as published by the pricing agency that establishes the AWP as used in this guarantee; c) Customer makes benefit changes that impact the guarantee; d) there is a material industry change in pricing methodologies resulting in a new source or benchmark;

• On specialty drugs, United will retain the difference between what United reimburses the Network Pharmacy and Customer's payment for a prescription drug product or service.

Specialty Drug

Category Drug Name LDD

Indicator Guarantee

Pricing

(AWP-%)

Specialty Drug

Category Drug Name LDD

Indicator Guarantee

Pricing

(AWP-%)

ANEMIA ARANESP No 15.30%

INFLAMMAT

ORY

CONDITION

S COSENTYX No 14.30%

ANEMIA EPOGEN No 14.10%

INFLAMMAT

ORY

CONDITION

S DUPIXENT No 14.90%

ANEMIA PROCRIT No 14.40%

INFLAMMAT

ORY EMFLAZA Yes 11.80%

CONDITION

S

ANEMIA RETACRIT No 14.90%

INFLAMMAT

ORY

CONDITION

S ENBREL No 15.30%

ANTICONVU

LSANT DIACOMIT Yes 13.30%

INFLAMMAT

ORY

CONDITION

S HUMIRA No 16.90%

ANTICONVU

LSANT EPIDIOLEX Yes 13.30%

INFLAMMAT

ORY

CONDITION

S ILUMYA No 14.90%

ANTICONVU

LSANT FINTEPLA Yes 11.30%

INFLAMMAT

ORY

CONDITION

S KEVZARA No 10.70%

ANTICONVU

LSANT ZTALMY Yes 11.30%

INFLAMMAT

ORY

CONDITION

S KINERET Yes 14.30%

ANTIHYPER

LIPIDEMIC JUXTAPID Yes 14.10%

INFLAMMAT

ORY

CONDITION

S OLUMIANT Yes 13.30%

ANTI-

INFECTIVE ARIKAYCE Yes 13.80%

INFLAMMAT

ORY

CONDITION

S OPZELURA No 11.80%

ANTI-

INFECTIVE DARAPRIM Yes 13.30%

INFLAMMAT

ORY

CONDITION

S ORENCIA No 15.00%

ANTI-

INFECTIVE

PYRIMETHA

MINE No 13.30%

INFLAMMAT

ORY

CONDITION

S OTEZLA No 14.80%

ANTIVIRAL LIVTENCITY Yes 13.80%

INFLAMMAT

ORY

CONDITION

S RIDAURA No 14.90%

ASTHMA FASENRA Yes 13.30%

INFLAMMAT

ORY

CONDITION

S RINVOQ No 14.90%

ASTHMA NUCALA Yes 13.30%

INFLAMMAT

ORY

CONDITION

S SILIQ Yes 12.30%

ASTHMA XOLAIR Yes 13.30%

INFLAMMAT

ORY

CONDITION

S SIMPONI No 14.90%

CARDIOVAS

CULAR CAMZYOS Yes 12.30%

INFLAMMAT

ORY

CONDITION

S SKYRIZI No 18.90%

CARDIOVAS

CULAR

DROXIDOP

A Yes 33.70%

INFLAMMAT

ORY

CONDITION

S SOTYKTU No 12.30%

CARDIOVAS

CULAR NORTHERA Yes 14.80%

INFLAMMAT

ORY

CONDITION

S STELARA No 16.90%

CARDIOVAS

CULAR VYNDAMAX Yes 16.10%

INFLAMMAT

ORY TALTZ No 12.30%

CONDITION

S

CARDIOVAS

CULAR VYNDAQEL Yes 13.30%

INFLAMMAT

ORY

CONDITION

S TREMFYA No 14.90%

CNS

AGENTS AUSTEDO No 14.30%

INFLAMMAT

ORY

CONDITION

S XELJANZ No 14.90%

CNS

AGENTS ENSPRYNG Yes 12.80%

INFLAMMAT

ORY

CONDITION

S

XELJANZ

XR No 14.90%

CNS

AGENTS EXSERVAN Yes 14.30%

IRON

OVERLOAD

DEFERASIR

OX Yes 66.70%

CNS

AGENTS FIRDAPSE Yes 11.30%

IRON

OVERLOAD

DEFERIPRO

NE Yes 33.70%

CNS

AGENTS HETLIOZ Yes 14.80%

IRON

OVERLOAD EXJADE Yes 13.00%

CNS

AGENTS INGREZZA Yes 13.80%

IRON

OVERLOAD FERRIPROX Yes 13.30%

CNS

AGENTS RADICAVA Yes 13.30%

IRON

OVERLOAD JADENU No 14.30%

CNS

AGENTS RELYVRIO Yes 12.30%

KIDNEY

DISEASE TARPEYO Yes 12.30%

CNS

AGENTS RILUTEK No 14.30%

LIVER

DISEASE OCALIVA Yes 15.90%

CNS

AGENTS RILUZOLE No 92.70%

MONOCLON

AL

ANTIBODY

MISCELLAN

EOUS BENLYSTA Yes 14.30%

CNS

AGENTS RUZURGI Yes 12.30%

MOOD

DISORDER

DRUGS SPRAVATO No 14.30%

CNS

AGENTS SABRIL Yes 16.90%

MULTIPLE

SCLEROSIS AMPYRA Yes 12.60%

CNS

AGENTS

SODIUM

OXYBATE Yes 7.20%

MULTIPLE

SCLEROSIS AUBAGIO No 13.30%

CNS

AGENTS

TASIMELTE

ON Yes 33.70%

MULTIPLE

SCLEROSIS AVONEX No 14.80%

CNS

AGENTS

TETRABEN

AZINE No 49.00%

MULTIPLE

SCLEROSIS BAFIERTAM Yes 14.80%

CNS

AGENTS TIGLUTIK Yes 11.30%

MULTIPLE

SCLEROSIS

BETASERO

N No 14.90%

CNS

AGENTS

VIGABATRI

N No 18.40%

MULTIPLE

SCLEROSIS COPAXONE No 15.50%

CNS

AGENTS

VIGADRON

E Yes 17.40%

MULTIPLE

SCLEROSIS

DALFAMPRI

DIN Yes 92.90%

CNS

AGENTS XENAZINE Yes 16.40%

MULTIPLE

SCLEROSIS

DIMETHYL

FUMARATE Yes 79.60%

CNS

AGENTS XYREM Yes 7.20%

MULTIPLE

SCLEROSIS EXTAVIA No 14.90%

CNS

AGENTS XYWAV Yes 8.20%

MULTIPLE

SCLEROSIS

FINGOLIMO

D No 69.40%

CYSTIC

FIBROSIS BETHKIS No 12.30%

MULTIPLE

SCLEROSIS GILENYA No 14.80%

CYSTIC

FIBROSIS

BRONCHIT

OL Yes 14.30%

MULTIPLE

SCLEROSIS

GLATIRAME

R No 79.60%

CYSTIC

FIBROSIS CAYSTON Yes 15.30%

MULTIPLE

SCLEROSIS GLATOPA No 79.60%

CYSTIC

FIBROSIS KALYDECO Yes 14.30%

MULTIPLE

SCLEROSIS KESIMPTA No 14.80%

CYSTIC

FIBROSIS

KITABIS

PAK No 13.30%

MULTIPLE

SCLEROSIS

MAVENCLA

D Yes 14.80%

CYSTIC

FIBROSIS ORKAMBI Yes 14.30%

MULTIPLE

SCLEROSIS MAYZENT No 14.80%

CYSTIC

FIBROSIS

PULMOZYM

E No 15.90%

MULTIPLE

SCLEROSIS PLEGRIDY Yes 14.30%

CYSTIC

FIBROSIS SYMDEKO Yes 14.30%

MULTIPLE

SCLEROSIS PONVORY Yes 11.80%

CYSTIC

FIBROSIS TOBI No 14.60%

MULTIPLE

SCLEROSIS REBIF No 14.80%

CYSTIC

FIBROSIS

TOBI

PODHALER No 14.60%

MULTIPLE

SCLEROSIS

REBIF

REBIDOSE No 14.80%

CYSTIC

FIBROSIS

TOBRAMYCI

N No 69.40%

MULTIPLE

SCLEROSIS TECFIDERA Yes 14.80%

CYSTIC

FIBROSIS TRIKAFTA Yes 14.30%

MULTIPLE

SCLEROSIS VUMERITY Yes 13.30%

ENDOCRIN

E BETAINE Yes 11.30%

MULTIPLE

SCLEROSIS ZEPOSIA Yes 13.30%

ENDOCRIN

E BUPHENYL No 15.60%

MUSCULOS

KELETAL

AGENTS EVRYSDI Yes 8.20%

ENDOCRIN

E BYNFEZIA No 9.20%

MUSCULOS

KELETAL

AGENTS VOXZOGO Yes 12.30%

ENDOCRIN

E CARBAGLU Yes 8.20%

NARCOLEP

SY WAKIX Yes 14.30%

ENDOCRIN

E

CARGLUMI

C Yes 33.70%

NEUTROPE

NIA FULPHILA No 14.60%

ENDOCRIN

E CHENODAL Yes 10.20%

NEUTROPE

NIA GRANIX No 14.60%

ENDOCRIN

E CLOVIQUE No 33.70%

NEUTROPE

NIA LEUKINE No 14.60%

ENDOCRIN

E

CORTROPH

IN Yes 11.30%

NEUTROPE

NIA NEULASTA No 14.60%

ENDOCRIN

E CUPRIMINE No 14.90%

NEUTROPE

NIA NEUPOGEN No 14.60%

ENDOCRIN

E

CYSTADAN

E Yes 11.30%

NEUTROPE

NIA NIVESTYM No 14.60%

ENDOCRIN

E

CYSTADRO

PS Yes 11.30%

NEUTROPE

NIA NYVEPRIA No 12.30%

ENDOCRIN

E CYSTARAN Yes 13.80%

NEUTROPE

NIA UDENYCA No 14.60%

ENDOCRIN

E

DEPEN

TITRATABS No 14.80%

NEUTROPE

NIA ZARXIO No 14.60%

ENDOCRIN

E

DICHLORPH

ENAMIDE Yes 13.80%

NEUTROPE

NIA ZIEXTENZO No 14.30%

ENDOCRIN

E

D- PENAMINE No 13.80%

ONCOLOGY

INJECTABL

E ELIGARD No 13.40%

ENDOCRIN

E EGRIFTA Yes 14.30%

ONCOLOGY

INJECTABL

E INTRON A Yes 14.30%

ENDOCRIN

E FIRMAGON No 14.30%

ONCOLOGY

INJECTABL

E

LEUPROLID

E No 63.30%

ENDOCRIN

E GATTEX Yes 15.60%

ONCOLOGY

INJECTABL

E SYNRIBO Yes 14.60%

ENDOCRIN

E

H.P.

ACTHAR Yes 14.30%

ONCOLOGY

- ORAL

ABIRATERO

NE No 82.70%

ENDOCRIN

E IMCIVREE Yes 14.30%

ONCOLOGY

- ORAL AFINITOR No 14.90%

ENDOCRIN

E ISTURISA Yes 11.30%

ONCOLOGY

- ORAL

AFINITOR

DISPERZ No 14.90%

ENDOCRIN

E JAVYGTOR Yes 12.30%

ONCOLOGY

- ORAL ALECENSA Yes 14.90%

ENDOCRIN

E JYNARQUE Yes 13.30%

ONCOLOGY

- ORAL ALKERAN No 16.30%

ENDOCRIN

E KEVEYIS Yes 13.80%

ONCOLOGY

- ORAL ALUNBRIG Yes 12.80%

ENDOCRIN

E KORLYM Yes 12.30%

ONCOLOGY

- ORAL AYVAKIT Yes 15.30%

ENDOCRIN

E KUVAN Yes 13.50%

ONCOLOGY

- ORAL BALVERSA Yes 14.30%

ENDOCRIN

E

LANREOTID

E No 11.30%

ONCOLOGY

- ORAL

BEXAROTE

NE No 34.10%

ENDOCRIN

E MYALEPT Yes 8.20%

ONCOLOGY

- ORAL BOSULIF Yes 14.30%

ENDOCRIN

E MYCAPSSA Yes 12.30%

ONCOLOGY

- ORAL BRAFTOVI Yes 14.80%

ENDOCRIN

E NATPARA Yes 14.10%

ONCOLOGY

- ORAL BRUKINSA Yes 13.80%

ENDOCRIN

E NITYR Yes 13.80%

ONCOLOGY

- ORAL

CABOMETY

X Yes 13.30%

ENDOCRIN

E

OCTREOTID

E ACETATE No 57.30%

ONCOLOGY

- ORAL

CALQUENC

E Yes 14.30%

ENDOCRIN

E

PENICILLAM

INE No 33.70%

ONCOLOGY

- ORAL

CAPECITABI

NE No 82.70%

ENDOCRIN

E PROCYSBI Yes 8.20%

ONCOLOGY

- ORAL CAPRELSA Yes 10.20%

ENDOCRIN

E RAVICTI Yes 15.90%

ONCOLOGY

- ORAL COMETRIQ Yes 13.80%

ENDOCRIN

E RECORLEV Yes 14.60%

ONCOLOGY

- ORAL COPIKTRA Yes 15.30%

ENDOCRIN

E SAMSCA Yes 14.30%

ONCOLOGY

- ORAL COTELLIC Yes 13.30%

ENDOCRIN

E

SANDOSTA

TIN No 14.60%

ONCOLOGY

- ORAL DAURISMO Yes 13.30%

ENDOCRIN

E

SAPROPTE

RIN Yes 41.90%

ONCOLOGY

- ORAL ERIVEDGE Yes 13.30%

ENDOCRIN

E SIGNIFOR Yes 8.20%

ONCOLOGY

- ORAL ERLEADA No 14.30%

ENDOCRIN

E

SODIUM

PHENYLBU

TYRATE No 33.70%

ONCOLOGY

- ORAL ERLOTINIB Yes 33.70%

ENDOCRIN

E

SOMATULIN

E DEPOT No 14.30%

ONCOLOGY

- ORAL ETOPOSIDE No 33.70%

ENDOCRIN

E SOMAVERT Yes 11.50%

ONCOLOGY

- ORAL

EVEROLIMU

S No 45.90%

ENDOCRIN

E SYPRINE No 14.30%

ONCOLOGY

- ORAL EXKIVITY Yes 13.80%

ENDOCRIN

E THIOLA Yes 12.30%

ONCOLOGY

- ORAL FARYDAK Yes 12.30%

ENDOCRIN

E TIOPRONIN No 33.70%

ONCOLOGY

- ORAL FOTIVDA Yes 14.10%

ENDOCRIN

E TOLVAPTAN No 33.70%

ONCOLOGY

- ORAL GAVRETO Yes 13.30%

ENDOCRIN

E TRIENTINE No 84.70%

ONCOLOGY

- ORAL GILOTRIF Yes 8.20%

ENDOCRIN

E XERMELO Yes 13.80%

ONCOLOGY

- ORAL GLEEVEC No 16.30%

ENDOCRIN

E XURIDEN Yes 13.30%

ONCOLOGY

- ORAL GLEOSTINE No 16.30%

ENZYME

DEFICIENC

Y CHOLBAM Yes 5.10%

ONCOLOGY

- ORAL HYCAMTIN No 15.60%

ENZYME

DEFICIENC

Y CYSTAGON Yes 11.80%

ONCOLOGY

- ORAL IBRANCE Yes 14.80%

ENZYME

DEFICIENC

Y GALAFOLD Yes 14.80%

ONCOLOGY

- ORAL ICLUSIG Yes 13.60%

ENZYME

DEFICIENC

Y MIGLUSTAT No 33.70%

- ORAL IDHIFA No 15.30%

ENZYME

DEFICIENC

Y NITISINONE No 33.70%

ONCOLOGY

- ORAL

IMATINIB

MESYLATE No 92.40%

ENZYME

DEFICIENC

Y ORFADIN No 3.10%

ONCOLOGY

- ORAL IMBRUVICA Yes 14.80%

ENZYME

DEFICIENC

Y PALYNZIQ Yes 12.30%

ONCOLOGY

- ORAL INLYTA Yes 14.40%

ENZYME

DEFICIENC

Y STRENSIQ Yes 12.10%

ONCOLOGY

- ORAL INQOVI Yes 11.30%

ENZYME

DEFICIENC

Y SUCRAID Yes 13.00%

ONCOLOGY

- ORAL INREBIC Yes 13.30%

ENZYME

DEFICIENC

Y TEGSEDI Yes 8.20%

ONCOLOGY

- ORAL IRESSA Yes 15.30%

ENZYME

DEFICIENC

Y ZAVESCA Yes 8.20%

ONCOLOGY

- ORAL JAKAFI Yes 13.30%

GAUCHERS

DISEASE CERDELGA Yes 14.30%

ONCOLOGY

- ORAL KISQALI No 15.30%

GENETIC

DISORDER DOJOLVI Yes 15.90%

ONCOLOGY

- ORAL

KISQALI

FEMARA No 15.90%

GENETIC

DISORDER VIJOICE No 13.30%

ONCOLOGY

- ORAL KOSELUGO Yes 14.60%

GENETIC

DISORDER ZOKINVY Yes 14.30%

ONCOLOGY

- ORAL LAPATINIB No 33.70%

GROWTH

HORMONE

DEFICIENC

Y

GENOTROP

IN No 14.90%

ONCOLOGY

- ORAL

LENALIDOM

IDE Yes 33.70%

GROWTH

HORMONE

DEFICIENC

Y

HUMATROP

E No 15.50%

ONCOLOGY

- ORAL LENVIMA Yes 15.30%

GROWTH

HORMONE

DEFICIENC

Y INCRELEX Yes 14.30%

ONCOLOGY

- ORAL LONSURF Yes 13.30%

GROWTH

HORMONE

DEFICIENC

Y

NORDITRO

PIN No 16.80%

ONCOLOGY

- ORAL LORBRENA Yes 12.30%

GROWTH

HORMONE

DEFICIENC

Y

NUTROPIN

AQ No 15.00%

ONCOLOGY

- ORAL LUMAKRAS Yes 13.30%

GROWTH

HORMONE

DEFICIENC

Y

OMNITROP

E No 15.30%

ONCOLOGY

- ORAL LYNPARZA Yes 13.00%

GROWTH

HORMONE

DEFICIENC

Y SAIZEN No 18.30%

ONCOLOGY

- ORAL MATULANE Yes 13.80%

GROWTH

HORMONE

DEFICIENC

Y SEROSTIM Yes 14.30%

ONCOLOGY

- ORAL MEKINIST Yes 12.30%

GROWTH

HORMONE

DEFICIENC

Y SKYTROFA No 12.30%

ONCOLOGY

- ORAL MEKTOVI Yes 14.80%

GROWTH

HORMONE

DEFICIENC

Y ZOMACTON No 15.50%

ONCOLOGY

- ORAL

MELPHALA

N No 33.70%

GROWTH

HORMONE

DEFICIENC

Y ZORBTIVE Yes 13.80%

ONCOLOGY

- ORAL MESNEX No 14.80%

HEMATOLO

GIC BERINERT Yes 13.30%

ONCOLOGY

- ORAL NERLYNX Yes 15.10%

HEMATOLO

GIC CABLIVI Yes 14.30%

ONCOLOGY

- ORAL NEXAVAR Yes 13.30%

HEMATOLO

GIC CINRYZE Yes 15.30%

ONCOLOGY

- ORAL NILANDRON No 15.90%

HEMATOLO

GIC DOPTELET Yes 14.30%

ONCOLOGY

- ORAL

NILUTAMID

E No 40.90%

HEMATOLO

GIC FIRAZYR Yes 15.10%

ONCOLOGY

- ORAL NINLARO No 14.30%

HEMATOLO

GIC HAEGARDA Yes 13.30%

ONCOLOGY

- ORAL NUBEQA Yes 14.30%

HEMATOLO

GIC ICATIBANT Yes 33.70%

ONCOLOGY

- ORAL ODOMZO No 14.60%

HEMATOLO

GIC MOZOBIL No 14.30%

ONCOLOGY

- ORAL ONUREG No 12.80%

HEMATOLO

GIC MULPLETA No 14.30%

ONCOLOGY

- ORAL ORGOVYX Yes 15.10%

HEMATOLO

GIC OXBRYTA Yes 12.80%

ONCOLOGY

- ORAL PEMAZYRE Yes 14.80%

HEMATOLO

GIC PROMACTA Yes 14.30%

ONCOLOGY

- ORAL PIQRAY No 12.80%

HEMATOLO

GIC REZUROCK Yes 14.10%

ONCOLOGY

- ORAL POMALYST Yes 13.80%

HEMATOLO

GIC RUCONEST Yes 14.10%

ONCOLOGY

- ORAL PURIXAN No 13.30%

HEMATOLO

GIC SAJAZIR Yes 23.50%

ONCOLOGY

- ORAL PYRUKYND Yes 12.30%

HEMATOLO

GIC TAKHZYRO Yes 14.30%

ONCOLOGY

- ORAL QINLOCK Yes 15.30%

HEMATOLO

GIC TAVALISSE Yes 14.30%

ONCOLOGY

- ORAL RETEVMO Yes 13.30%

HEMOPHILI

A - INFUSED ADVATE No 43.80%

ONCOLOGY

- ORAL REVLIMID Yes 15.60%

HEMOPHILI

A - INFUSED

ADYNOVAT

E No 34.70%

ONCOLOGY

- ORAL

ROZLYTRE

K No 16.30%

HEMOPHILI

A - INFUSED AFSTYLA No 34.60%

ONCOLOGY

- ORAL RUBRACA Yes 15.30%

HEMOPHILI

A - INFUSED

ALPHANATE

/VON

WILLEBRAN

D No 42.60%

ONCOLOGY

- ORAL RYDAPT No 16.30%

HEMOPHILI

A - INFUSED

ALPHANINE

SD No 49.80%

ONCOLOGY

- ORAL SCEMBLIX No 12.30%

HEMOPHILI

A - INFUSED ALPROLIX No 14.30%

ONCOLOGY

- ORAL SORAFENIB Yes 42.90%

HEMOPHILI

A - INFUSED BENEFIX No 15.30%

ONCOLOGY

- ORAL SPRYCEL No 16.30%

HEMOPHILI

A - INFUSED COAGADEX Yes 30.60%

ONCOLOGY

- ORAL STIVARGA Yes 12.80%

HEMOPHILI

A - INFUSED CORIFACT No 28.60%

ONCOLOGY

- ORAL SUNITINIB Yes 33.70%

HEMOPHILI

A - INFUSED ELOCTATE No 28.60%

ONCOLOGY

- ORAL SUTENT Yes 15.60%

HEMOPHILI

A - INFUSED ESPEROCT No 23.50%

ONCOLOGY

- ORAL TABLOID No 16.30%

HEMOPHILI

A - INFUSED FEIBA No 40.70%

ONCOLOGY

- ORAL TABRECTA No 13.30%

HEMOPHILI

A - INFUSED HEMOFIL M No 44.90%

ONCOLOGY

- ORAL TAFINLAR Yes 14.30%

HEMOPHILI

A - INFUSED HUMATE-P No 37.70%

ONCOLOGY

- ORAL TAGRISSO Yes 14.30%

HEMOPHILI

A - INFUSED IDELVION No 14.30%

- ORAL TALZENNA Yes 14.30%

HEMOPHILI

A - INFUSED IXINITY No 14.30%

ONCOLOGY

- ORAL TARCEVA Yes 16.20%

HEMOPHILI

A - INFUSED JIVI No 23.50%

ONCOLOGY

- ORAL TARGRETIN No 14.80%

HEMOPHILI

A - INFUSED KOATE No 42.90%

ONCOLOGY

- ORAL TASIGNA Yes 14.30%

HEMOPHILI

A - INFUSED KOATE-DVI No 42.90%

ONCOLOGY

- ORAL TAZVERIK Yes 14.60%

HEMOPHILI

A - INFUSED

KOGENATE

FS No 47.80%

ONCOLOGY

- ORAL TEMODAR No 15.60%

HEMOPHILI

A - INFUSED KOVALTRY No 46.20%

ONCOLOGY

- ORAL

TEMOZOLO

MIDE No 59.60%

HEMOPHILI

A - INFUSED MONONINE No 32.10%

ONCOLOGY

- ORAL TEPMETKO Yes 13.30%

HEMOPHILI

A - INFUSED

NOVOEIGH

T No 44.80%

ONCOLOGY

- ORAL THALOMID Yes 15.60%

HEMOPHILI

A - INFUSED

NOVOSEVE

N RT No 38.90%

ONCOLOGY

- ORAL TIBSOVO Yes 14.30%

HEMOPHILI

A - INFUSED NUWIQ No 48.70%

ONCOLOGY

- ORAL TRETINOIN No 84.70%

HEMOPHILI

A - INFUSED

PROFILNIN

E No 30.70%

ONCOLOGY

- ORAL TRUSELTIQ Yes 13.80%

HEMOPHILI

A - INFUSED REBINYN No 18.40%

ONCOLOGY

- ORAL TUKYSA Yes 14.60%

HEMOPHILI

A - INFUSED

RECOMBIN

ATE No 41.90%

ONCOLOGY

- ORAL TURALIO Yes 14.80%

HEMOPHILI

A - INFUSED RIXUBIS No 14.60%

ONCOLOGY

- ORAL TYKERB No 15.60%

HEMOPHILI

A - INFUSED

SEVENFAC

T No 23.50%

ONCOLOGY

- ORAL UKONIQ Yes 13.30%

HEMOPHILI

A - INFUSED TRETTEN Yes 15.20%

ONCOLOGY

- ORAL VENCLEXTA Yes 13.30%

HEMOPHILI

A - INFUSED VONVENDI Yes 13.30%

ONCOLOGY

- ORAL VERZENIO Yes 16.10%

HEMOPHILI

A - INFUSED WILATE No 42.90%

ONCOLOGY

- ORAL VITRAKVI Yes 15.30%

HE…